Amgen announced that the Food and Drug Administration (FDA) has approved Repatha (evolocumab) Pushtronex system, an on-body infusor with a prefilled cartridge intended for once-monthly administration.

The FDA approval of the Pushtronex once-a-month dosing system for evolocumab is a nice addition to our treatment regimen for patients with statin-refractory hypercholesterolemia.

Amgen announced that all Repatha (evolocumab) devices are now available at a 60% reduced list price. This includes the pre-filled syringe, the SureClick autoinjector, and the Pushtronex device, an ...

THOUSAND OAKS, Calif., Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha ® (evolocumab) Pushtronex ™ system (on-body infusor with prefilled cartridge), a ...

Amgen said the FDA has approved its Repatha (evolocumab) Pushtronex system, the first hands-free, once-monthly delivery option for a PCSK9 inhibitor. Evolocumab is indicated as an adjunct to diet ...

Amgen announced that as part of the company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and ...

Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or 'bad' cholesterol, also significantly lowers the ...

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine , 2015; 150315080057008 DOI: 10.1056/NEJMoa1500858 Cite This Page : ...

Amgen AMGN revealed that the Food and Drug Administration (FDA) has approved the Repatha (evolocumab) Pushtronex system, a fresh, monthly single-dose administration option. According to the ...

At 48 weeks in the evolocumab group, the LDL cholesterol level was reduced to 70 mg per deciliter (1.8 mmol per liter) or lower in 87% of the patients, to 40 mg per deciliter (1.0 mmol per liter ...

Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in phase 2 studies. We ...

The FINANCIAL -- Amgen on July 11 announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha (evolocumab) Pushtronex system (on-body infusor with prefilled cartridge), a ...